C

Cuorips Inc
TSE:4894

Watchlist Manager
Cuorips Inc
TSE:4894
Watchlist
Price: 4 740 JPY 0.42% Market Closed
Market Cap: 38.1B JPY
Have any thoughts about
Cuorips Inc?
Write Note

Net Margin
Cuorips Inc

-3 543.7%
Current
-3 544%
Average
-7.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-3 543.7%
=
Net Income
-1.1B
/
Revenue
31m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
JP
Cuorips Inc
TSE:4894
38B JPY
-3 544%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
315.2B USD
9%
US
Amgen Inc
NASDAQ:AMGN
141.9B USD
13%
US
Gilead Sciences Inc
NASDAQ:GILD
116.4B USD
0%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
104.5B USD
-5%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
135.7B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.7B USD
34%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
36B EUR
-14%
Country JP
Market Cap 38B JPY
Net Margin
-3 544%
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 315.2B USD
Net Margin
9%
Country US
Market Cap 141.9B USD
Net Margin
13%
Country US
Market Cap 116.4B USD
Net Margin
0%
Country US
Market Cap 104.5B USD
Net Margin
-5%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 135.7B AUD
Net Margin
18%
Country US
Market Cap 78.7B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 36B EUR
Net Margin
-14%
No Stocks Found

Cuorips Inc
Glance View

Market Cap
38B JPY
Industry
Biotechnology

Cuorips Inc is a Japan-based company mainly engaged in the development and commercialization of regenerative medical products and contract development and manufacturing organization (CDMO) business. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 46 full-time employees. The company went IPO on 2023-06-27. The main product of the Company is human iPS cell-derived cardiomyocyte sheets. The firm provides regenerative medical products for the heart and other areas through in-house research, joint research with universities and other research institutions and major pharmaceutical companies. The firm operates CDMO business using CLiC-1, a commercial cell culture and processing facility with an integrated laboratory based on the Company's original design concept.

Intrinsic Value
234.89 JPY
Overvaluation 95%
Intrinsic Value
Price
C

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-3 543.7%
=
Net Income
-1.1B
/
Revenue
31m
What is the Net Margin of Cuorips Inc?

Based on Cuorips Inc's most recent financial statements, the company has Net Margin of -3 543.7%.